{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T16:25:21Z","timestamp":1781540721590,"version":"3.54.5"},"reference-count":59,"publisher":"American Association for Cancer Research (AACR)","issue":"8","license":[{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,25]]},"abstract":"<jats:p>Multicellular spheroids comprised of malignant cells, endothelial cells, and mesenchymal stem cells served as an in vitro model of human solid tumors to investigate the potentiation of DNA-damaging drugs by pharmacologic modulation of DNA repair pathways. The DNA-damaging drugs, topotecan, trabectedin, and temozolomide were combined with varied inhibitors of DNA damage response enzymes including PARP (olaparib or talazoparib), ATM (ataxia telangiectasia mutated; AZD-1390), ATR (ataxia telangiectasia and Rad3-related protein; berzosertib or elimusertib), and DNA-PK (DNA-dependent protein kinase; nedisertib or VX-984). A range of clinically achievable concentrations were tested up to the clinical Cmax, if known. Mechanistically, the types of DNA damage induced by temozolomide, topotecan, and trabectedin are distinct, which was apparent from the response of spheroids to combinations with various DNA repair inhibitors. Although most combinations resulted in additive cytotoxicity, synergistic activity was observed for temozolomide combined with PARP inhibitors as well as combinations of the ATM inhibitor AZD-1390 with either topotecan or trabectedin. These findings might provide guidance for the selection of anticancer agent combinations worthy of further investigation.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Clinical efficacy of DNA-damaging anticancer drugs can be influenced by the DNA damage response in tumor cells. The potentiation of DNA-damaging drugs by pharmacologic modulation of DNA repair pathways was assessed in multicellular tumor spheroids. Although most combinations demonstrated additive cytotoxicity, synergistic cytotoxicity was observed for several drug combinations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-23-0193","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T09:34:02Z","timestamp":1690796042000},"page":"1648-1661","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs"],"prefix":"10.1158","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6444-3121","authenticated-orcid":true,"given":"Thomas S.","family":"Dexheimer","sequence":"first","affiliation":[{"name":"1Molecular Pharmacology Laboratories, Applied and Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3896-7909","authenticated-orcid":true,"given":"Nathan P.","family":"Coussens","sequence":"additional","affiliation":[{"name":"1Molecular Pharmacology Laboratories, Applied and Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7907-1177","authenticated-orcid":true,"given":"Thomas","family":"Silvers","sequence":"additional","affiliation":[{"name":"1Molecular Pharmacology Laboratories, Applied and Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6730-9439","authenticated-orcid":true,"given":"John","family":"Wright","sequence":"additional","affiliation":[{"name":"2Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6156-1393","authenticated-orcid":true,"given":"Joel","family":"Morris","sequence":"additional","affiliation":[{"name":"2Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4463-1790","authenticated-orcid":true,"given":"James H.","family":"Doroshow","sequence":"additional","affiliation":[{"name":"2Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1535-7304","authenticated-orcid":true,"given":"Beverly A.","family":"Teicher","sequence":"additional","affiliation":[{"name":"2Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,8,25]]},"reference":[{"key":"2023082514065366400_bib1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1146\/annurev-med-081313-121208","article-title":"The DNA damage response: implications for tumor responses to radiation and chemotherapy","volume":"66","author":"Goldstein","year":"2015","journal-title":"Annu Rev Med"},{"key":"2023082514065366400_bib2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"2023082514065366400_bib3","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"2023082514065366400_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"2023082514065366400_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/978-3-319-13278-5_2","article-title":"DNA damaging drugs","volume-title":"Molecular therapies of cancer","author":"Weber","year":"2015"},{"key":"2023082514065366400_bib6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41392-020-00358-6","article-title":"Development of synthetic lethality in cancer: molecular and cellular classification","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"2023082514065366400_bib7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.dnarep.2014.03.014","article-title":"DNA double-strand break repair pathway choice and cancer","volume":"19","author":"Aparicio","year":"2014","journal-title":"DNA Repair"},{"key":"2023082514065366400_bib8","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1200\/JCO.18.02050","article-title":"Moving from poly (ADP-Ribose) polymerase inhibition to targeting DNA repair and DNA damage response in cancer therapy","volume":"37","author":"Gourley","year":"2019","journal-title":"J Clin Oncol"},{"key":"2023082514065366400_bib9","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.molcel.2020.04.035","article-title":"Biomarker-guided development of DNA repair inhibitors","volume":"78","author":"Cleary","year":"2020","journal-title":"Mol Cell"},{"key":"2023082514065366400_bib10","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol Cell"},{"key":"2023082514065366400_bib11","doi-asserted-by":"crossref","first-page":"107450","DOI":"10.1016\/j.pharmthera.2019.107450","article-title":"Targeting ATR as cancer therapy: a new era for synthetic lethality and synergistic combinations?","volume":"207","author":"Bradbury","year":"2020","journal-title":"Pharmacol Ther"},{"key":"2023082514065366400_bib12","first-page":"23","article-title":"ATM: functions of ATM kinase and Its relevance to hereditary tumors","author":"Ueno","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2023082514065366400_bib13","doi-asserted-by":"crossref","first-page":"107391","DOI":"10.1016\/j.pharmthera.2019.07.002","article-title":"ATM in DNA repair in cancer","volume":"203","author":"Jin","year":"2019","journal-title":"Pharmacol Ther"},{"key":"2023082514065366400_bib14","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1535-7163.MCT-16-0378","article-title":"AZD6738, a novel oral inhibitor of ATR, induces synthetic lethality with ATM deficiency in gastric cancer cells","volume":"16","author":"Min","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"2023082514065366400_bib15","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1158\/0008-5472.CAN-17-0634","article-title":"ATM deficiency generating genomic instability sensitizes pancreatic ductal adenocarcinoma cells to therapy-induced DNA damage","volume":"77","author":"Perkhofer","year":"2017","journal-title":"Cancer Res"},{"key":"2023082514065366400_bib16","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1158\/0008-5472.CAN-16-3398","article-title":"ATM deficiency is associated with sensitivity to PARP1- and ATR inhibitors in lung adenocarcinoma","volume":"77","author":"Schmitt","year":"2017","journal-title":"Cancer Res"},{"key":"2023082514065366400_bib17","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1182\/blood-2010-01-265769","article-title":"The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo","volume":"116","author":"Weston","year":"2010","journal-title":"Blood"},{"key":"2023082514065366400_bib18","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.3390\/cancers12113389","article-title":"Beyond DNA repair: DNA-PKcs in tumor metastasis, metabolism and immunity","volume":"12","author":"Yang","year":"2020","journal-title":"Cancers"},{"key":"2023082514065366400_bib19","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.molcel.2016.02.010","article-title":"Two-stage synapsis of DNA ends during non-homologous end joining","volume":"61","author":"Graham","year":"2016","journal-title":"Mol Cell"},{"key":"2023082514065366400_bib20","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s002800050994","article-title":"Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide","volume":"44","author":"Beale","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"2023082514065366400_bib21","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1586\/era.12.37","article-title":"Molecular mechanisms of temozolomide resistance in glioblastoma multiforme","volume":"12","author":"Johannessen","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"key":"2023082514065366400_bib22","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.gendis.2016.04.007","article-title":"Temozolomide resistance in glioblastoma multiforme","volume":"3","author":"Lee","year":"2016","journal-title":"Genes Dis"},{"key":"2023082514065366400_bib23","doi-asserted-by":"crossref","first-page":"109875","DOI":"10.1016\/j.biopha.2020.109875","article-title":"The role of single strand break repair pathways in cellular responses to camptothecin induced DNA damage","volume":"125","author":"Mei","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"2023082514065366400_bib24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0079-6603(06)81005-6","article-title":"Repair of topoisomerase I-mediated DNA damage","volume":"81","author":"Pommier","year":"2006","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"key":"2023082514065366400_bib25","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1158\/1078-0432.CCR-19-1089","article-title":"Targeting topoisomerase I in the era of precision medicine","volume":"25","author":"Thomas","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2023082514065366400_bib26","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1158\/1535-7163.MCT-10-0263","article-title":"A review of trabectedin (ET-743): a unique mechanism of action","volume":"9","author":"D'Incalci","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"2023082514065366400_bib27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/fon.13.207","article-title":"Trabectedin mechanism of action: what's new?","volume":"9","author":"D'Incalci","year":"2013","journal-title":"Future Oncol"},{"key":"2023082514065366400_bib28","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00280-015-2918-1","article-title":"Unique features of trabectedin mechanism of action","volume":"77","author":"Larsen","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"2023082514065366400_bib29","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/annonc\/mdv071","article-title":"Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study","volume":"26","author":"Monk","year":"2015","journal-title":"Ann Oncol"},{"key":"2023082514065366400_bib30","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.ejca.2011.01.016","article-title":"Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study","volume":"47","author":"Schoffski","year":"2011","journal-title":"Eur J Cancer"},{"key":"2023082514065366400_bib31","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/annonc\/mdu134","article-title":"Activity of trabectedin in germline BRCA1\/2-mutated metastatic breast cancer: results of an international first-in-class phase II study","volume":"25","author":"Delaloge","year":"2014","journal-title":"Ann Oncol"},{"key":"2023082514065366400_bib32","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1177\/24725552211038362","article-title":"Complex tumor spheroids, a tissue-mimicking tumor model, for drug discovery and precision medicine","volume":"26","author":"Kaur","year":"2021","journal-title":"SLAS Discov"},{"key":"2023082514065366400_bib33","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/MPH.0b013e3182002f9f","article-title":"ASPS-1, a novel cell line manifesting key features of alveolar soft part sarcoma","volume":"33","author":"Kenney","year":"2011","journal-title":"J Pediatr Hematol Oncol"},{"key":"2023082514065366400_bib34","first-page":"589","article-title":"Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay","volume":"48","author":"Alley","year":"1988","journal-title":"Cancer Res"},{"key":"2023082514065366400_bib35","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jnci\/83.11.757","article-title":"Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines","volume":"83","author":"Monks","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"2023082514065366400_bib36","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann Appl Biol"},{"key":"2023082514065366400_bib37","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1124\/pr.117.013755","article-title":"Small-molecule screens: a gateway to cancer therapeutic agents with case studies of food and drug administration-approved drugs","volume":"69","author":"Coussens","year":"2017","journal-title":"Pharmacol Rev"},{"key":"2023082514065366400_bib38","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41571-018-0007-1","article-title":"Targeting the tumour stroma to improve cancer therapy","volume":"15","author":"Valkenburg","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2023082514065366400_bib39","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1471-2407-14-151","article-title":"Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide","volume":"14","author":"Tentori","year":"2014","journal-title":"BMC Cancer"},{"key":"2023082514065366400_bib40","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.canlet.2012.01.007","article-title":"DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis","volume":"332","author":"Roos","year":"2013","journal-title":"Cancer Lett"},{"key":"2023082514065366400_bib41","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/neuonc\/noab003","article-title":"PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma","volume":"23","author":"Wu","year":"2021","journal-title":"Neuro Oncol"},{"key":"2023082514065366400_bib42","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1158\/1078-0432.CCR-14-2572","article-title":"Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program","volume":"21","author":"Smith","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2023082514065366400_bib43","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.18632\/oncotarget.28273","article-title":"Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy","volume":"13","author":"Ueno","year":"2022","journal-title":"Oncotarget"},{"key":"2023082514065366400_bib44","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1158\/1078-0432.CCR-16-1040","article-title":"PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer","volume":"23","author":"Lok","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2023082514065366400_bib45","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1158\/1535-7163.MCT-21-0934","article-title":"A new class of selective ATM inhibitors as combination partners of DNA double-strand break inducing cancer therapies","volume":"21","author":"Zimmermann","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"2023082514065366400_bib46","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1158\/0008-5472.CAN-13-0110","article-title":"ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status","volume":"73","author":"Huntoon","year":"2013","journal-title":"Cancer Res"},{"key":"2023082514065366400_bib47","doi-asserted-by":"crossref","first-page":"6968","DOI":"10.1158\/0008-5472.CAN-13-3369","article-title":"ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses","volume":"74","author":"Josse","year":"2014","journal-title":"Cancer Res"},{"key":"2023082514065366400_bib48","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1535-7163.MCT-20-1026","article-title":"Novel and highly potent ATR inhibitor M4344 kills cancer cells with replication stress, and enhances the chemotherapeutic activity of widely used DNA damaging agents","volume":"20","author":"Jo","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"2023082514065366400_bib49","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","article-title":"The novel ATR inhibitor BAY 1895344 Is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models","volume":"19","author":"Wengner","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"2023082514065366400_bib50","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1200\/JCO.2017.76.6915","article-title":"Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors","volume":"36","author":"Thomas","year":"2018","journal-title":"J Clin Oncol"},{"key":"2023082514065366400_bib51","doi-asserted-by":"crossref","first-page":"107518","DOI":"10.1016\/j.pharmthera.2020.107518","article-title":"Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): clinical candidate for cancer therapy","volume":"210","author":"Gorecki","year":"2020","journal-title":"Pharmacol Ther"},{"key":"2023082514065366400_bib52","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov"},{"key":"2023082514065366400_bib53","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1158\/0008-5472.CAN-21-1756","article-title":"DNA-PKcs: a targetable protumorigenic protein kinase","volume":"82","author":"Dylgjeri","year":"2022","journal-title":"Cancer Res"},{"key":"2023082514065366400_bib54","doi-asserted-by":"crossref","first-page":"107617","DOI":"10.1016\/j.pharmthera.2020.107617","article-title":"DNA-PK in human malignant disorders: mechanisms and implications for pharmacological interventions","volume":"215","author":"Medova","year":"2020","journal-title":"Pharmacol Ther"},{"key":"2023082514065366400_bib55","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3389\/fonc.2019.00635","article-title":"DNA-PK as an emerging therapeutic target in cancer","volume":"9","author":"Mohiuddin","year":"2019","journal-title":"Front Oncol"},{"key":"2023082514065366400_bib56","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1158\/2159-8290.CD-14-0358","article-title":"Beyond DNA repair: DNA-PK function in cancer","volume":"4","author":"Goodwin","year":"2014","journal-title":"Cancer Discov"},{"key":"2023082514065366400_bib57","doi-asserted-by":"crossref","first-page":"18882","DOI":"10.1038\/s41598-019-54796-6","article-title":"Activity of M3814, an oral DNA-PK inhibitor, in combination with topoisomerase II inhibitors in ovarian cancer models","volume":"9","author":"Wise","year":"2019","journal-title":"Sci Rep"},{"key":"2023082514065366400_bib58","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1158\/1535-7163.MCT-17-1267","article-title":"The DNA-PK inhibitor VX-984 enhances the radiosensitivity of glioblastoma cells grown in vitro and as orthotopic xenografts","volume":"17","author":"Timme","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"2023082514065366400_bib59","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw368.25","article-title":"Preclinical characterization of the selective DNA-dependent protein kinase (DNA-PK) inhibitor VX-984 in combination with chemotherapy","volume":"27","author":"Boucher","year":"2016","journal-title":"Ann Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-23-0193\/3351625\/crc-23-0193.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/8\/1648\/3359758\/crc-23-0193.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/8\/1648\/3359758\/crc-23-0193.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T10:07:35Z","timestamp":1692958055000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/3\/8\/1648\/728621\/Multicellular-Complex-Tumor-Spheroid-Response-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":59,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,25]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-23-0193","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.24033665","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033677","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808155.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033641","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033653","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033662.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033665.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033668.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808155","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808143","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033647.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033653.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808140","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033650.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033656.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033650","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033662","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033674","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033659.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033641.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033644.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808152","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033677.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033647","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033659","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033671","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033671.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808149","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033674.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808137","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033644","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033656","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033668","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808137.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808152.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808146","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808140.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808143.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808149.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808146.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.24033674.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808149.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808149","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033647","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808137","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033659","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033659.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033671","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033656.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033641.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808140.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808152","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808140","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808146.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808143.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6767408.v2","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6767408","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033650.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033668","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033644","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033656","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033653.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033662.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033677.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033665.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033671.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808143","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033668.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6767408.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808155","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033653","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033665","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033677","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808152.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808155.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033641","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808137.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033647.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033644.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23808146","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033650","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033674","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24033662","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,25]]}}}